{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T05:38:36Z","timestamp":1769751516386,"version":"3.49.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T00:00:00Z","timestamp":1765065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15214-5","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T23:45:37Z","timestamp":1765064737000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting Musashi-2 to counteract senescence and resistance in chronic myeloid leukemia: enhancing the efficacy of imatinib therapy"],"prefix":"10.1186","volume":"26","author":[{"given":"Khadija","family":"Arif","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Yousaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilawar","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,7]]},"reference":[{"key":"15214_CR1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00277-015-2325-z","volume":"94","author":"B Chereda","year":"2015","unstructured":"Chereda B, Melo JV. Natural course and biology of CML. Ann Hematol. 2015;94:107\u201321.","journal-title":"Ann Hematol"},{"key":"15214_CR2","doi-asserted-by":"crossref","unstructured":"Melo BC&JV. The biology and pathogenesis of chronic myeloid leukemia. In Hehlmann R. Chronic Myeloid Leukemia.: Springer; 2016. p. 17\u201339.","DOI":"10.1007\/978-3-319-33198-0_2"},{"key":"15214_CR3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11899-012-0114-5","volume":"7","author":"T Skorski","year":"2012","unstructured":"Skorski T. Genetic mechanisms of chronic myeloid leukemia blastic transformation. Curr Hematol Malignancy Rep. 2012;7:87\u201393.","journal-title":"Curr Hematol Malignancy Rep"},{"issue":"9","key":"15214_CR4","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMra013339","volume":"346","author":"G David","year":"2002","unstructured":"David G, Savage KHA. Imatinib mesylate\u2013a new oral targeted therapy. N Engl J Med. 2002;346(9):683\u201393.","journal-title":"N Engl J Med"},{"issue":"5","key":"15214_CR5","first-page":"1958","volume":"6","author":"Carsten Oetzel","year":"2000","unstructured":"C Oetzel . The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X. Clin Cancer Res. 2000; 6(5).","journal-title":"Clinical Cancer Research"},{"key":"15214_CR6","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s11899-015-0248-3","volume":"10","author":"A Christopher","year":"2015","unstructured":"Christopher A, Eide TO. chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors. Curr Hematol Malig Rep. 2015;10:158\u201366.","journal-title":"Curr Hematol Malig Rep"},{"issue":"14","key":"15214_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14143300","volume":"14","author":"G Poudel","year":"2022","unstructured":"Poudel G, Tolland MG, Hughes TP, Pagani IS. Mechanisms of resistance and implications for treatment strategies in chronic myeloid leukaemia. Cancers (Basel). 2022;14(14):3300.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"15214_CR8","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1182\/blood-2012-03-380147","volume":"120","author":"R Hehlmann","year":"2012","unstructured":"Hehlmann R. How I treat CML blast crisis. Blood. 2012;120(4):737\u201347.","journal-title":"Blood"},{"issue":"5","key":"15214_CR9","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.clml.2013.03.018","volume":"13","author":"EJ Jabbour","year":"2013","unstructured":"Jabbour EJ, Cortes JE, Kantarjian HM. Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options. Clin Lymphoma Myeloma Leuk. 2013;13(5):515\u201329.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"15214_CR10","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1111\/cas.14035","volume":"110","author":"T Tsujino","year":"2019","unstructured":"Tsujino T, Sugito N, Taniguchi K, Honda R, Komura K, Yoshikawa Y, et al. Microrna-143\/Musashi-2\/KRAS cascade contributes positively to carcinogenesis in human bladder cancer. Cancer Sci. 2019;110(7):2189\u201399.","journal-title":"Cancer Sci"},{"issue":"28","key":"15214_CR11","doi-asserted-by":"publisher","first-page":"10969","DOI":"10.1074\/jbc.RA119.007220","volume":"294","author":"CE Cragle","year":"2019","unstructured":"Cragle CE, MacNicol MC, Byrum SD, Hardy LL, Mackintosh SG, Richardson WA, et al. Musashi interaction with poly(A)-binding protein is required for activation of target mRNA translation. J Biol Chem. 2019;294(28):10969\u201386.","journal-title":"J Biol Chem"},{"key":"15214_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.969632","volume":"12","author":"L Jiang","year":"2022","unstructured":"Jiang L, Xue S, Xu J, Fu X, Wei J, Zhang C. Prognostic value of Musashi 2 (MSI2) in cancer patients: a systematic review and meta-analysis. Front Oncol. 2022;12:969632.","journal-title":"Front Oncol"},{"issue":"2","key":"15214_CR13","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3109\/10428194.2015.1055478","volume":"57","author":"S Lu","year":"2015","unstructured":"Lu S, Mu Q, Yu M, Yin X, Chen J, Jin J. Overexpression of musashi2 is possibly associated with chemoresistance in T-cell acute lymphoblastic leukemia. Leuk Lymphoma. 2015;57(2):467\u20139.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"15214_CR14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.trecan.2017.03.007","volume":"3","author":"MG Kharas","year":"2017","unstructured":"Kharas MG, Lengner CJ. Stem cells, cancer and MUSASHI in blood and guts. Trends Cancer. 2017;3(5):347\u201356.","journal-title":"Trends Cancer"},{"issue":"3","key":"15214_CR15","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1172\/JCI78440","volume":"125","author":"SM Park","year":"2015","unstructured":"Park SM, G\u00f6nen M, Vu L, Minuesa G, Tivnan P, Barlowe TS, et al. Musashi2 sustains the mixed-lineage leukemia\u2013driven stem cell regulatory program. J Clin Invest. 2015;125(3):1286\u201398.","journal-title":"J Clin Invest"},{"key":"15214_CR16","doi-asserted-by":"crossref","unstructured":"Kharas MG, Lengner CJ, Al-Shahrour F, Bullinger L, Ball B, Zaidi S, et al. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med. 2010;16(8):903\u20138.","DOI":"10.1038\/nm.2187"},{"key":"15214_CR17","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nature09171","volume":"466","author":"T Ito","year":"2010","unstructured":"Ito T, Kwon HY, Zimdahl B, Congdon KL, Blum J, Lento WE, et al. Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature. 2010;466:765\u20138.","journal-title":"Nature"},{"key":"15214_CR18","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1038\/s41388-025-03415-y","volume":"44","author":"M Wagstaff","year":"2025","unstructured":"Wagstaff M, Sevim O, Goff A, Raynor M, Park H, Mancini EJ, et al. \u03b2-catenin interacts with canonical RBPs including MSI2 to associate with a Wnt signalling mRNA network in myeloid leukaemia cells. Oncogene. 2025;44:2490\u2013503.","journal-title":"Oncogene"},{"issue":"1","key":"15214_CR19","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.yexcr.2013.09.009","volume":"320","author":"H Zhang","year":"2014","unstructured":"Zhang H, Tan S, Wang J, Chen S, Quan J, Xian J, et al. Musashi2 modulates K562 leukemic cell proliferation and apoptosis involving the MAPK pathway. Exp Cell Res. 2014;320(1):119\u201327.","journal-title":"Exp Cell Res"},{"issue":"2691","key":"15214_CR20","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1038\/s41467-019-10523-3","volume":"10","author":"G Minuesa","year":"2019","unstructured":"Minuesa G, Albanese SK, Xie W, Kazansky Y, Worroll D, Chow A, et al. Small-molecule targeting of MUSASHI RNA-binding activity in acute myeloid leukemia. Nat Commun. 2019;10(2691):2691.","journal-title":"Nat Commun"},{"issue":"6","key":"15214_CR21","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s13238-015-0143-7","volume":"6","author":"RX Hong Zhou","year":"2015","unstructured":"Hong Zhou RX. Leukemia stem cells: the root of chronic myeloid leukemia. Protein Cell. 2015;6(6):403\u201312.","journal-title":"Protein Cell"},{"key":"15214_CR22","first-page":"246","volume":"130","author":"R Bhatia","year":"2019","unstructured":"Bhatia R. Targeting leukemia stem cell resistance in chronic myelogenous leukemia. Transact American Clin Climatolog Assoc. 2019;130:246.","journal-title":"Transact American Clin Climatolog Assoc"},{"issue":"9","key":"15214_CR23","doi-asserted-by":"publisher","first-page":"713","DOI":"10.18632\/oncotarget.333","volume":"2","author":"AGT Jean-Claude Chomel","year":"2011","unstructured":"Jean-Claude Chomel . Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy. Oncotarget. 2011;2(9):713\u201327.","journal-title":"Oncotarget"},{"issue":"8","key":"15214_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2012.111","volume":"3","author":"C Drullion","year":"2012","unstructured":"Drullion C, Tr\u00e9goat C, Lagarde V, Tan S, Gioia R, Priault M, et al. Apoptosis and autophagy have opposite roles on imatinib-induced K562 leukemia cell senescence. Cell Death Dis. 2012;3(8):e373.","journal-title":"Cell Death Dis"},{"issue":"24","key":"15214_CR25","doi-asserted-by":"publisher","first-page":"6175","DOI":"10.1182\/bloodadvances.2020003117","volume":"4","author":"Y Tanabe","year":"2020","unstructured":"Tanabe Y, Kawamoto S, Takaku T, Morishita S, Hirao A, Komatsu N, et al. Expansion of senescent megakaryocyte-lineage cells maintains CML cell leukemogenesis. Blood Adv. 2020;4(24):6175\u201388.","journal-title":"Blood Adv"},{"issue":"14","key":"15214_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23147715","volume":"23","author":"O Prado-Carrillo","year":"2022","unstructured":"Prado-Carrillo O, Arenas-Ram\u00edrez A, Llaguno-Munive M, Jurado R, P\u00e9rez-Rojas J, Cervera-Ceballos E, et al. Ketoconazole reverses imatinib resistance in human chronic myelogenous leukemia K562 cells. Int J Mol Sci. 2022;23(14):7715.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"15214_CR27","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/0145-2126(92)90114-M","volume":"16","author":"DC Marks","year":"1992","unstructured":"Marks DC, Belov L, Davey MW, Davey RA, Kidman AD. The MTT cell viability assay for cytotoxicity testing in multidrug-resistant human leukemic cells. Leukemia Res. 1992;16(12):1165\u201373.","journal-title":"Leukemia Res"},{"key":"15214_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08450-y","volume":"21","author":"M Fatima","year":"2021","unstructured":"Fatima M, Kakar SJ, Adnan F, Khan K, Mian AA, Khan D. AXL receptor tyrosine kinase: a possible therapeutic target in acute promyelocytic leukemia. BMC Cancer. 2021;21:713.","journal-title":"BMC Cancer"},{"issue":"92","key":"15214_CR29","first-page":"51998","volume":"27","author":"S Borowicz","year":"2014","unstructured":"Borowicz S, Van Scoyk M, Avasarala S, Rathinam MK, Tauler J, Bikkavilli RK, et al. The soft agar colony formation assay. J Vis Exper. 2014;27(92):51998.","journal-title":"J Vis Exper"},{"key":"15214_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12958-4","volume":"24","author":"BB Nadeem","year":"2024","unstructured":"Nadeem BB, Bibi A, Khan M, Sajjad GR, Adnan F, Ahmad Z, et al. Effects of imidazole derivatives on cellular proliferation and apoptosis in myeloid leukemia. BMC Cancer. 2024;24:1200.","journal-title":"BMC Cancer"},{"issue":"S3","key":"15214_CR31","doi-asserted-by":"publisher","first-page":"e1313111","DOI":"10.1097\/01.HS9.0000974192.13131.11","volume":"7","author":"S Maham","year":"2023","unstructured":"Maham S, Awan SN, Adnan F, Kakar SJ, Mian A, Khan D. PB1837: antibiotics; a possible alternate treatment option for myeloid leukemia. HemaSphere. 2023;7(S3):e1313111.","journal-title":"HemaSphere"},{"issue":"1","key":"15214_CR32","first-page":"25","volume":"5","author":"YR Saadat","year":"2015","unstructured":"Saadat YR, Saeidi N, Vahed SZ, Barzegari A, Barar J. An update to DNA ladder assay for apoptosis detection. Bioimpacts. 2015;5(1):25\u20138.","journal-title":"Bioimpacts"},{"key":"15214_CR33","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/nature17665","volume":"532","author":"S Rentas","year":"2016","unstructured":"Rentas S, Holzapfel NT, Belew MS, Pratt GA, Voisin V, Wilhelm BT, et al. Musashi-2 attenuates AHR signalling to expand human haematopoietic stem cells. Nature. 2016;532:508\u201311.","journal-title":"Nature"},{"issue":"10","key":"15214_CR34","doi-asserted-by":"publisher","first-page":"979","DOI":"10.4161\/cbt.10.10.14010","volume":"10","author":"N Lori","year":"2010","unstructured":"Lori N, Griner GWR. Aggressive myeloid leukemia formation is directed by the Musashi 2\/Numb pathway. Cancer Biol Ther. 2010;10(10):979\u201382.","journal-title":"Cancer Biol Ther"},{"issue":"7","key":"15214_CR35","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.3109\/10428194.2014.981175","volume":"56","author":"J Kaeda","year":"2015","unstructured":"Kaeda J, Ringel F, Oberender C, Mills K, Quintarelli C, Pane F, et al. Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia. Leuk Lymphoma. 2015;56(7):2105\u201313.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"15214_CR36","first-page":"581","volume":"22","author":"F Moradi","year":"2019","unstructured":"Moradi F, Babashah S, Sadeghizadeh M, Jalili A, Hajifathali A, Roshandel H. Signaling pathways involved in chronic myeloid leukemia pathogenesis: the importance of targeting Musashi2-Numb signaling to eradicate leukemia stem cells. Iranian J Basic Med Sci. 2019;22(6):581\u20139.","journal-title":"Iranian J Basic Med Sci"},{"key":"15214_CR37","doi-asserted-by":"crossref","unstructured":"Jain VR&MV. In Vitro Tumorigenic Assay: Colony Forming Assay for Cancer Stem Cells. In Walker JM, editor. Methods in Molecular Biology.: Humana Press, New York, NY; 2017. p. 89\u201395.","DOI":"10.1007\/978-1-4939-7401-6_8"},{"key":"15214_CR38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.scr.2018.01.038","volume":"28","author":"S Bono","year":"2018","unstructured":"Bono S, Sbarba PD, Lulli M. Imatinib-mesylate enhances the maintenance of chronic myeloid leukemia stem cell potential in the absence of glucose. Stem Cell Res. 2018;28:33\u20138.","journal-title":"Stem Cell Res"},{"issue":"11","key":"15214_CR39","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1084\/jem.20110304","volume":"208","author":"C Hurtz","year":"2011","unstructured":"Hurtz C, Hatzi K, Cerchietti L, Braig M, Park E, Kim YM, et al. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med. 2011;208(11):2163\u201374.","journal-title":"J Exp Med"},{"issue":"6","key":"15214_CR40","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1096\/fj.201601240R","volume":"31","author":"W Sheng","year":"2017","unstructured":"Sheng W, Dong M, Chen C, Wang Z, Li Y, Wang K, et al. Cooperation of Musashi-2, Numb, MDM2, and P53 in drug resistance and malignant biology of pancreatic cancer. FASEB J. 2017;31(6):2429\u201338.","journal-title":"FASEB J"},{"key":"15214_CR41","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026104","volume":"6","author":"J Chen","year":"2016","unstructured":"Chen J. The cell-cycle arrest and apoptotic functions of p53 in tumor initiation and progression. Cold Spring Harb Perspect Med. 2016;6:3.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"15214_CR42","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1172\/JCI35721","volume":"121","author":"AS Corbin","year":"2010","unstructured":"Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2010;121(1):396\u2013409.","journal-title":"J Clin Invest"},{"issue":"21","key":"15214_CR43","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1182\/blood.V116.21.203.203","volume":"116","author":"I Jedema","year":"2010","unstructured":"Jedema I, van Dreunen L, Hagedoorn RS, Falkenburg JF. Multi-dimensional resistance phenotype allows subpopulation of quiescent chronic myeloid leukemia stem cells to universally escape from therapeutic attack. Blood. 2010;116(21):203.","journal-title":"Blood"},{"issue":"1","key":"15214_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10637-016-0397-9","volume":"31","author":"SL Lompard\u00eda","year":"2017","unstructured":"Lompard\u00eda SL, D\u00edaz M, Papademetrio DL, Pibuel M, \u00c1lvarez \u00c9, Hajos SE. 4-methylumbelliferone and imatinib combination enhances senescence induction in chronic myeloid leukemia cell lines. Investigat New Drugs. 2017;31(1):1\u201310.","journal-title":"Investigat New Drugs"},{"key":"15214_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2012.111","volume":"3","author":"C Drullion","year":"2012","unstructured":"Drullion C, Tr\u00e9goat C, Lagarde V, Tan S, Gioia R, Priault M, et al. Apoptosis and autophagy have opposite roles on imatinib-induced K562 leukemia cell senescence. Cell Death Dis. 2012;3:e373.","journal-title":"Cell Death Dis"},{"issue":"1","key":"15214_CR46","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/15384047.2017.1385675","volume":"19","author":"H Was","year":"2018","unstructured":"Was H, Czarnecka J, Kominek A, Barszcz K, Bernas T, Piwocka K, et al. Some chemotherapeutics-treated colon cancer cells display a specific phenotype being a combination of stem-like and senescent cell features. Cancer Biol Ther. 2018;19(1):63\u201375.","journal-title":"Cancer Biol Ther"},{"issue":"10","key":"15214_CR47","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1093\/jnci\/djab064","volume":"113","author":"PG Prasanna","year":"2021","unstructured":"Prasanna PG, Citrin DE, Hildesheim J, Ahmed MM, Venkatachalam S, Riscuta G, et al. Therapy-induced senescence: opportunities to improve anticancer therapy. JNCI J Natl Cancer Inst. 2021;113(10):1285\u201398.","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"463","key":"15214_CR48","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.canlet.2019.08.004","volume":"28","author":"CAOC Olivier Pluquet","year":"2019","unstructured":"Olivier Pluquet CAOC. Connecting cancer relapse with senescence. Cancer Lett. 2019;28(463):50\u20138.","journal-title":"Cancer Lett"},{"key":"15214_CR49","first-page":"645593","volume":"9","author":"Kumari Ruchi","year":"2021","unstructured":"Ruchi K . Mechanisms of cellular senescence: cell cycle arrest and senescence associated secretory phenotype. Cell Dev Biol. 2021;9:645593.","journal-title":"Cell Dev Biol"},{"key":"15214_CR50","doi-asserted-by":"crossref","unstructured":"Yalda Hekmatshoar TOBAGSBAKAZKAS. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.\u00a0Cell Mol Biol (Noisy-le-grand). 2018; 64(3): 23\u201330.","DOI":"10.14715\/cmb\/2018.64.6.5"},{"key":"15214_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2012.111","volume":"3","author":"C Drullion","year":"2012","unstructured":"Drullion C, Tr\u00e9goat C, Lagarde V, Tan S, Gioia R, Priault M, et al. Apoptosis and autophagy have opposite roles on imatinib-induced K562 leukemia cell senescence. Cell Death Dis. 2012;3:e373.","journal-title":"Cell Death Dis"},{"issue":"1","key":"15214_CR52","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ccr.2010.04.025","volume":"18","author":"MA Gregory","year":"2010","unstructured":"Gregory MA, Phang TL, Neviani P, Alvarez-Calderon F, Eide CA, O\u2019Hare T, et al. Wnt\/Ca2+\/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. Cancer Cell. 2010;18(1):74\u201387.","journal-title":"Cancer Cell"},{"key":"15214_CR53","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s12185-013-1318-8","volume":"98","author":"T Ito","year":"2013","unstructured":"Ito T. Stem cell maintenance and disease progression in chronic myeloid leukemia. Int J Hematol. 2013;98:641\u20137.","journal-title":"Int J Hematol"},{"key":"15214_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03327-4","volume":"9","author":"L Zhang","year":"2018","unstructured":"Zhang L, Zhou H, Li X, Vartuli RL, Rowse M, Xing Y, et al. Eya3 partners with PP2A to induce c-Myc stabilization and tumor progression. Nat Commun. 2018;9:1047.","journal-title":"Nat Commun"},{"key":"15214_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1534","volume":"9","author":"A Kaidi","year":"2007","unstructured":"Kaidi A, Williams AC, Paraskeva C. Interaction between \u03b2-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nat Cell Biol. 2007;9:210.","journal-title":"Nat Cell Biol"},{"key":"15214_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.912942","volume":"12","author":"V Singh","year":"2022","unstructured":"Singh V, Singh R, Kushwaha R, Verma SP, Tripathi AK, Mahdi AA. The molecular role of HIF1\u03b1 is elucidated in chronic myeloid leukemia. Front Oncol. 2022;12:912942.","journal-title":"Front Oncol"},{"issue":"18","key":"15214_CR57","doi-asserted-by":"publisher","first-page":"5244","DOI":"10.1158\/0008-5472.CAN-13-3012","volume":"74","author":"J Roos","year":"2014","unstructured":"Roos J, Oancea C, Heinssmann M, Khan D, Held H, Kahnt AS, et al. 5-lipoxygenase is a candidate target for therapeutic management of stem cell\u2013like cells in acute myeloid leukemia. Cancer Res. 2014;74(18):5244\u201355.","journal-title":"Cancer Res"},{"key":"15214_CR58","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1007\/s12185-010-0615-8","volume":"91","author":"KN Rice","year":"2010","unstructured":"Rice KN, Jamieson CH. Molecular pathways to CML stem cells. Int J Hematol. 2010;91:748\u201352.","journal-title":"Int J Hematol"},{"key":"15214_CR59","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/leu.2008.262","volume":"23","author":"Y Hu","year":"2008","unstructured":"Hu Y, Chen Y, Douglas L, Li S. \u03b2-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Leukemia. 2008;23:109\u201316.","journal-title":"Leukemia"},{"issue":"5","key":"15214_CR60","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1111\/j.1349-7006.2009.01123.x","volume":"100","author":"N Ohtani","year":"2009","unstructured":"Ohtani N, Mann DJ, Hara E. Cellular senescence: its role in tumor suppression and aging. Cancer Sci. 2009;100(5):792.","journal-title":"Cancer Sci"},{"key":"15214_CR61","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/s41568-022-00450-9","volume":"22","author":"L Wang","year":"2022","unstructured":"Wang L, Lankhorst L, Bernards R. Exploiting senescence for the treatment of cancer. Nat Rev Cancer. 2022;22:340\u201355.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"15214_CR62","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","volume":"103","author":"DP Bruno Calabretta","year":"2004","unstructured":"Bruno Calabretta DP. The biology of CML blast crisis. Blood. 2004;103(11):4010\u201322.","journal-title":"Blood"},{"issue":"2","key":"15214_CR63","first-page":"1","volume":"3","author":"M Khan","year":"2020","unstructured":"Khan M, Din M, Naeem Z, Sajid Z, Khan D, Amjad MD, et al. Insights into Acute myeloid leukemia: critical analysis on its wide aspects. Abasyn J Life Sci. 2020;3(2):1\u20139.","journal-title":"Abasyn J Life Sci"},{"issue":"8","key":"15214_CR64","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1093\/nar\/gkw207","volume":"44","author":"CG Bennett","year":"2016","unstructured":"Bennett CG, Riemondy K, Chapnick DA, Bunker E, Liu X, Kuersten S, et al. Genome-wide analysis of Musashi-2 targets reveals novel functions in governing epithelial cell migration. Nucleic Acids Res. 2016;44(8):3799\u2013800.","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"15214_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092699","volume":"12","author":"D Kang","year":"2020","unstructured":"Kang D, Lee Y, Lee JS. RNA-binding proteins in cancer: functional and therapeutic perspectives. Cancers (Basel). 2020;12(9):2699.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"15214_CR66","first-page":"433","volume":"1","author":"P Valent","year":"2007","unstructured":"Valent P. Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches. Biologics. 2007;1(4):433\u201348.","journal-title":"Biologics"},{"issue":"5","key":"15214_CR67","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ccr.2010.03.011","volume":"17","author":"B Zhang","year":"2010","unstructured":"Zhang B, Strauss AC, Chu S, Li M, Ho Y, Shiang KD, et al. Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell. 2010;17(5):427\u201342.","journal-title":"Cancer Cell"},{"issue":"4","key":"15214_CR68","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/stem.5530130416","volume":"13","author":"F Lanza","year":"1995","unstructured":"Lanza F, Bi S. Role of p53 in leukemogenesis of chronic myeloid leukemia. Stem Cells. 1995;13(4):445\u201352.","journal-title":"Stem Cells"},{"issue":"10","key":"15214_CR69","doi-asserted-by":"publisher","first-page":"4144","DOI":"10.1172\/JCI68951","volume":"123","author":"P Neviani","year":"2013","unstructured":"Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest. 2013;123(10):4144\u201357.","journal-title":"J Clin Invest"},{"key":"15214_CR70","doi-asserted-by":"crossref","unstructured":"Simona Soverini MMLBMCGM. Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Moelcular Cancer. 2018.","DOI":"10.1186\/s12943-018-0780-6"},{"key":"15214_CR71","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nature18288","volume":"534","author":"SA Abraham","year":"2016","unstructured":"Abraham SA, Hopcroft LE, Carrick E, Drotar ME, Dunn K, Williamson AJ, et al. Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells. Nature. 2016;534:341\u20136.","journal-title":"Nature"},{"issue":"7","key":"15214_CR72","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.3324\/haematol.2018.202846","volume":"104","author":"Rhys G. Morgan","year":"2019","unstructured":"Rhys G. Morgan JRMPKJHMCWADAGSDACWABMLWATRLD. LEF-1 drives aberrant \u03b2-catenin nuclear localization in myeloid leukemia cells. heamtologica. 2019; 104(7). https:\/\/doi.org\/10.3324\/haematol.2018.202846","journal-title":"heamatologica"},{"issue":"24","key":"15214_CR73","first-page":"27","volume":"15","author":"JA DraganaMilojkovic","year":"2009","unstructured":"DraganaMilojkovic JA. Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia. Clin Cancer Res. 2009;15(24):27.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"15214_CR74","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1172\/JCI35721","volume":"121","author":"AS Corbin","year":"2011","unstructured":"Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2011;121(1):396\u2013409.","journal-title":"J Clin Invest"},{"issue":"22","key":"15214_CR75","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1182\/blood.V128.22.2746.2746","volume":"128","author":"C Chiriches","year":"2016","unstructured":"Chiriches C, Khan D, Guillen N, Rokicki M, Guy C, Mian A, et al. A network of activated cancer signaling pathways in a high risk subgroup of acute myeloid leukemia targetable by SRC-kinase inhibitors. Blood. 2016;128(22):2746.","journal-title":"Blood"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15214-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15214-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15214-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T10:02:28Z","timestamp":1767866548000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-15214-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,7]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15214"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15214-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,7]]},"assertion":[{"value":"28 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}